| Drug Name: | Felbamate (25451-15-4) |
|---|---|
| PubChem ID: | 3331 |
| SMILES: | C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N |
| InchiKey: | WKGXYQFOCVYPAC-UHFFFAOYSA-N |
| Therapeutic Category: | Anticonvulsants, Central Nervous System Agents |
| Molecular Weight (dalton) | : | 238.243 |
| LogP | : | 0.9608 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 104.64 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Carbamazepine (298-46-4) | Reduce Serum Carbamazepine Levels | Synergistic | uncertain | In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine |
| Phenobarbital (50-06-6) | Ataxia | Synergistic | Not established. It seems possible that the felbamate may inhibit more than one pathway in the metabolism of the phenobarbital, resulting in a reduction in its loss from the body. The cytochrome P450 isoenzyme CYP2C19 may be involved | Pharmacokinetic interactions with felbamate In vitro-in vivo correlation |
| Valproic Acid (99-66-1) | Cognitive Disturbances | Synergistic | Uncertain,Felbamate may cause inhibition of the oxidative pathway of valproate metabolism | The effect of felbamate on valproic acid disposition |
| Valproic Acid (99-66-1) | Drowsiness | Synergistic | Uncertain,Felbamate may cause inhibition of the oxidative pathway of valproate metabolism | The effect of felbamate on valproic acid disposition |
| Valproic Acid (99-66-1) | Headaches | Synergistic | Uncertain,Felbamate may cause inhibition of the oxidative pathway of valproate metabolism | The effect of felbamate on valproic acid disposition |
| Valproic Acid (99-66-1) | Lethargy | Synergistic | Uncertain,Felbamate may cause inhibition of the oxidative pathway of valproate metabolism | The effect of felbamate on valproic acid disposition |
| Valproic Acid (99-66-1) | Low Platelet Counts | Synergistic | Uncertain,Felbamate may cause inhibition of the oxidative pathway of valproate metabolism | The effect of felbamate on valproic acid disposition |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hepatotoxicity | Cytochrome P450 3A4 (P08684) | Felbamate appears to induce the activity of CYP3A4@ which would account for it reducing plasma concentrations of carbamazepine or the progestin gestodene. [ ADR Type 2 ] | A mechanistic approach to antiepileptic drug interactions |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category